{"filings":[{"id":482076,"accession_number":"0000885725-26-000042","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2026-05-18T11:17:15+00:00","items":["8.01","9.01"],"status":"ready","headline":"Boston Scientific enters $2B accelerated share repurchase, expects $0.02 EPS accretion in FY2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ASR with JPMorgan for $2B; receives ~30.4M shares upfront at $52.68 (80% of repurchase price).","Final settlement expected by June 30, 2026; total shares based on VWAP during term less discount.","After completion, $3B remains under $5B share repurchase authorization.","Expected net impact to adjusted EPS in FY2026 is $0.02 accretive to prior guidance (Apr 22, 2026)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":482080,"accession_number":"0000885725-26-000041","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2026-05-18T11:15:03+00:00","items":["8.01","9.01"],"status":"ready","headline":"Boston Scientific invests $1.5B for ~34% stake in MiRus, gains option to acquire TAVR system for $3B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Paid $1.5B cash for 33.75% non-voting equity in MiRus; exclusive call option to buy TAVR business for $3.0B upon clinical/regulatory milestones.","SIEGEL TAVR valve uses proprietary rhenium alloy, nickel-free, balloon-expandable, delivered through 8 Fr sheath; still investigational.","Option includes right to acquire mitral/tricuspid replacement assets; if option not exercised, equity stake forfeited or reduced ~75%.","MiRus initiated STAR pivotal trial (up to 1,025 patients) evaluating SIEGEL valve; early feasibility study presented in 2025.","Investment expected immaterial to 2026 adjusted EPS; collaboration aims to bring differentiated TAVR system to aortic stenosis market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99448,"accession_number":"0000885725-26-000036","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Boston Scientific stockholders approve charter amendments and ESPP share increase at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved removal of supermajority voting provisions and officer exculpation under Delaware law.","All 10 director nominees elected with majority votes; no contested seats.","Ratified Ernst & Young as independent auditor for 2026 fiscal year.","Approved amendment to Employee Stock Purchase Plan to increase reserved shares.","Stockholders did not approve proposals to allow 25% shareholders to call special meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99447,"accession_number":"0000885725-26-000031","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Boston Scientific Q1 2026 net sales $5.20B (+11.6% reported), adj EPS $0.80 (guidance $0.78-$0.80)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $0.90 vs $0.45 YoY; adjusted EPS $0.80 vs $0.75 YoY, at top of guidance.","Cardiovascular segment net sales $3.50B (+13.5% reported); MedSurg $1.70B (+7.8% reported).","FY2026 guidance: organic growth 6.5-8.0%; adj EPS $3.34-$3.41. Q2: organic growth 5.0-7.0%; adj EPS $0.82-$0.84.","WATCHMAN FLX trial (CHAMPION-AF) met all endpoints; FARAPULSE PFA showed superior long-term AF outcomes.","Acquired Valencia Technologies (eCoin system for urge incontinence); elected Cathy Smith and Christophe Weber to board."],"consensus_eps_estimate":null,"consensus_eps_actual":0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":5203000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115454,"accession_number":"0000885725-26-000029","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Boston Scientific reports positive HI-PEITHO and CHAMPION-AF trial results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["HI-PEITHO: EKOS plus anticoagulation reduced primary endpoint events by 61% vs anticoagulation alone (4.0% vs 10.3%, P=0.005).","HI-PEITHO: No episodes of intracranial bleeding through 30 days; results published in NEJM.","CHAMPION-AF: WATCHMAN FLX showed 45% relative reduction in non-procedural major bleeding vs NOACs (10.9% vs 19.0%, P<0.001).","CHAMPION-AF: Primary efficacy endpoint met with non-inferiority to NOACs for stroke, CV death, or systemic embolism (5.7% vs 4.8%).","Both trials presented at ACC.26 and simultaneously published in The New England Journal of Medicine; data support expanded indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115453,"accession_number":"0000885725-26-000017","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Boston Scientific enters $11B credit facilities; $8B committed for Penumbra acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$3.0B revolving credit agreement matures Feb 2031 with two one-year extension options.","$2.0B 364-day revolving credit agreement tied to Penumbra acquisition; matures 364 days post-close.","$6.0B term loan agreement: $1B Tranche A and $5B Tranche B, both 364-day delayed draw at closing.","Tranche B Loans must be prepaid with net proceeds from equity or debt issuance after closing.","Prior $3.0B 2021 revolving credit agreement terminated upon entry into the new facilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115452,"accession_number":"0000885725-26-000013","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Boston Scientific boosts buyback by $4B to $5B; appoints two new directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved additional $4.0B stock repurchase authorization, total available now $5.0B.","Board expanded from 10 to 12; appointed Catherine R. Smith (CFO of Starbucks) and Christophe P. Weber (CEO of Takeda).","Smith and Weber will serve on audit and compensation committees; standard prorated compensation until 2026 annual meeting.","Former directors John Sununu and Yoshiaki Fujimori will not stand for re-election at 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115451,"accession_number":"0000885725-26-000008","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Yoshiaki Fujimori will not stand for re-election at Boston Scientific's 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Yoshiaki Fujimori informed Boston Scientific on Feb 2, 2026, that he will not seek re-election.","Fujimori has served on the Board since July 2016 and chairs the Risk, Science and Technology Committee.","He will continue as director and committee chair until the 2026 Annual Meeting.","Departure is not due to any disagreement with the company; Board will evaluate potential replacements.","The Nominating and Governance Committee will consider adding directors to the Board after his departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115450,"accession_number":"0000885725-26-000006","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Boston Scientific reports Q4 and full year 2025 results, announces acquisitions","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net sales $5.286B, up 15.9% reported; GAAP EPS $0.45, adjusted EPS $0.80.","FY2025 net sales $20.074B, up 19.9%; GAAP net income $2.898B, adjusted EPS $3.06.","Agreed to acquire Penumbra (PEN), a thrombectomy and neurovascular company.","Agreed to acquire Valencia Technologies for its eCoin tibial nerve stimulation device.","Completed acquisition of Nalu Medical for peripheral nerve stimulation system."],"consensus_eps_estimate":null,"consensus_eps_actual":1.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":20074000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115449,"accession_number":"0000947871-26-000037","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Boston Scientific to acquire Penumbra for $374 cash or 3.8721 BSX shares per share (73.26% cash/26.74% stock mix)","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Penumbra shareholders elect cash ($374/share) or stock (3.8721 BSX shares/share); proration targets 73.26% cash, 26.74% stock.","Penumbra termination fee $525M if superior proposal accepted; BSX pays $900M if regulatory blocks after approval.","Closing conditions include Penumbra stockholder vote, HSR clearance, S-4 effectiveness, and no material adverse effect.","Outstanding Penumbra options and RSUs convert to cash/BSX stock based on formulas; certain RSUs assumed by BSX.","Transaction expected to close in H1 2026, subject to conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115448,"accession_number":"0000947871-26-000034","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Boston Scientific to acquire Penumbra for ~$14.5B enterprise value ($374/share)","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Deal consideration: ~73% cash, ~27% stock; $374 per Penumbra share; enterprise value ~$14.5B.","Penumbra Q4 2025 revenue growth 21.4-22.0%; FY2025 revenue ~$1.4B (+17.3-17.5% YoY).","Transaction expected to close in 2026; subject to Penumbra stockholder approval and customary conditions.","First full year adj. EPS dilutive $0.06-0.08; neutral to slightly accretive in year two.","Expands Boston Scientific into mechanical thrombectomy and neurovascular adjacencies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131876,"accession_number":"0000885725-25-000052","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Boston Scientific approves 2026 annual bonus and performance share programs with similar structure to 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2026 Annual Bonus Plan approved; bonus pool 0%-150% of target based on global sales, adjusted EPS, operating income, and sustainability goals.","2026 rTSR PSP measures TSR vs S&P 500 Healthcare Index over 3 years (2026-2028); awards 0%-200% of target.","2026 Organic Net Sales PSP measures organic net sales growth vs financial plan over 3 years; awards 0%-200% of target.","Both performance programs forfeit if retirement before Jan 1, 2027; all awards subject to clawback policies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131875,"accession_number":"0000885725-25-000048","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"John Sununu to not stand for re-election to Boston Scientific board at 2026 meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John E. Sununu will not stand for re-election at the 2026 Annual Meeting; no disagreement cited.","He has served as director since April 2009, currently on Audit Committee and chairs Nominating and Governance.","Sununu will continue in his director and committee roles until the 2026 Annual Meeting.","Board will evaluate whether to add directors following Sununu's departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131874,"accession_number":"0000885725-25-000046","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Boston Scientific Q3 sales $5.065B (+20.3% reported) beat guidance; adjusted EPS $0.75 beats $0.70-0.72","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $755M ($0.51 EPS) vs $469M ($0.32) a year ago; adjusted EPS $0.75 vs $0.63.","Cardiovascular sales $3.343B (+22.4% reported); MedSurg $1.722B (+16.4%).","U.S. sales +27.0% reported; EMEA +2.6% reported but -2.0% operational due to ACURATE discontinuation.","FY2025 guidance: reported sales growth ~20%, organic ~15.5%; GAAP EPS $1.97-2.01, adjusted EPS $3.02-3.04.","Agreed to acquire Nalu Medical (neuromodulation) and acquired Elutia's antibiotic-eluting Envelope products."],"consensus_eps_estimate":null,"consensus_eps_actual":1.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":14788000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148455,"accession_number":"0000885725-25-000043","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Boston Scientific EVP/Peripheral Interventions President Mirviss to retire in Dec 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey B. Mirviss will retire as EVP and President, Peripheral Interventions effective Dec 1, 2025.","He will stay as senior advisor from Dec 1, 2025 through Feb 27, 2026 at $705,000 prorated salary.","No successor named; retirement agreement mirrors terms under Executive Retirement Plan and incentive programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148454,"accession_number":"0000885725-25-000039","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Boston Scientific Q2 net sales $5.06B (+22.8% reported); adj. EPS $0.75 beat guidance; raises FY outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $0.53 ($797M net income) vs $0.22 a year ago; adjusted EPS $0.75 vs guidance $0.71-0.73.","Q2 organic net sales growth 17.4% (guidance 13-15%); US sales up 30.7% reported.","Cardiovascular segment grew 26.8% reported; MedSurg up 15.7% reported.","FY2025 guidance raised: organic growth 14-15%; adjusted EPS $2.95-2.99 (prior $2.82-2.87).","Closed acquisitions of Intera Oncology and SoniVie; received expanded FDA label for FARAPULSE PFA System."],"consensus_eps_estimate":null,"consensus_eps_actual":0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":9724000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167275,"accession_number":"0000885725-25-000033","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Boston Scientific discontinues ACURATE aortic valve systems globally; maintains adjusted EPS guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinuing worldwide sales of ACURATE neo2 and ACURATE Prime Aortic Valve Systems; no longer pursuing U.S. FDA or other approvals.","Decision driven by increased regulatory requirements and prohibitive additional investments needed to maintain or obtain approvals.","Still expects to achieve Q2 and full year 2025 reported and organic sales and adjusted EPS guidance issued on April 23.","Not reaffirming Q2 and full year 2025 GAAP EPS guidance at this time; more details on Q2 2025 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167274,"accession_number":"0000885725-25-000028","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Boston Scientific stockholders elect all 10 director nominees and approve advisory votes at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 10 director nominees elected; votes ranged from ~1.147B (Mahoney) to ~1.239B (Pegus) in favor.","Advisory Say-on-Pay approved with 91.9% of votes cast in favor (1.139B for, 100.8M against).","Ratification of Ernst & Young as auditor for FY2025 passed with 91.4% of total votes cast (1.207B for).","Stockholder proposal 'Support Simple Majority Vote' passed advisory vote with 95.9% approval (1.178B for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167273,"accession_number":"0000885725-25-000024","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Boston Scientific CFO Dan Brennan to retire; Jon Monson named successor effective June 30, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dan Brennan retires as EVP & CFO effective June 29, 2025; will remain senior advisor to October 3, 2025.","Jon Monson promoted to EVP & CFO effective June 30, 2025; previously SVP, Investor Relations and global controller.","Monson receives base salary of $700,000, bonus target of 80%, and $1.75M equity award vesting over 4 years.","Monson has been with Boston Scientific for 25+ years; played key roles in finance during pandemic and strategic investments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167272,"accession_number":"0000885725-25-000023","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Boston Scientific Q1 sales $4.66B (+20.9% reported, +18.2% organic), EPS beat guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $0.45 (up 36% YoY); adjusted EPS $0.75, above guidance $0.66-0.68.","Cardiovascular segment sales grew 26.2% reported (25.6% organic); MedSurg +11.7% reported (+5.3% organic).","U.S. sales up 31.1%; EMEA +5.5%, APAC +8.2%, LACA +4.4%.","FY2025 outlook: organic +12-14%, adj. EPS $2.87-$2.94; Q2: organic +13-15%, adj. EPS $0.71-$0.73.","Closed Bolt Medical acquisition; agreed to acquire SoniVie Ltd. for TIVUS hypertension denervation technology."],"consensus_eps_estimate":null,"consensus_eps_actual":0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":4663000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184609,"accession_number":"0000885725-25-000013","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Boston Scientific subsidiary prices €1.5B senior notes to refinance 2025 maturity","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["AMS Europe issued €850M 3.000% notes due 2031 and €650M 3.250% notes due 2034.","Net proceeds of approximately €1.487B after underwriting discount and expenses.","Proceeds will fund repayment of AMS Europe's 0.750% notes due March 8, 2025.","Remaining proceeds for general corporate purposes including acquisitions.","Notes are fully and unconditionally guaranteed by Boston Scientific."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184608,"accession_number":"0000885725-25-000009","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Charles J. Dockendorff not standing for re-election to Boston Scientific board at 2025 Annual Meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Charles J. Dockendorff will not stand for re-election at the 2025 Annual Meeting, effective after meeting.","Dockendorff has served on board since April 2015, currently on Audit and Risk Committees; departure not due to disagreement.","Board will evaluate whether to add new directors following his departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184607,"accession_number":"0000885725-25-000007","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Boston Scientific Q4 revenue $4.56B (+22% YoY) beats guidance; adj EPS $0.70; FY25 organic guide 10-12%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $4.561B (+22.4% reported, 19.5% organic); GAAP EPS $0.38, adjusted EPS $0.70 vs guidance $0.64-0.66.","Full year 2024 net sales $16.747B (+17.6% reported); GAAP EPS $1.25, adjusted EPS $2.51.","Cardiovascular segment grew 28.8% reported; U.S. sales up 30.7%.","Guidance: Q1 2025 adj EPS $0.66-0.68, FY 2025 adj EPS $2.80-2.87; organic growth 10-12% for FY.","Completed acquisitions of Axonics and Cortex; announced deals for Bolt Medical and Intera Oncology."],"consensus_eps_estimate":null,"consensus_eps_actual":1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":16747000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184606,"accession_number":"0000885725-25-000003","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Boston Scientific reaches preliminary settlement of derivative lawsuits over LOTUS Edge recall","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["On January 8, 2025, a U.S. district court granted preliminary approval of a settlement of two shareholder derivative actions related to the LOTUS Edge recall.","The proposed settlement, dated September 6, 2024, includes corporate governance reforms such as amendments to committee charters and insider trading policy.","A final approval hearing is scheduled for March 25, 2025 at 2:00 p.m. Eastern Time.","The derivative lawsuits alleged breaches of fiduciary duty and violations related to the prior recall and retirement of the LOTUS Edge Aortic Valve System.","Under the settlement, Boston Scientific will adopt governance reforms to remain in effect for at least three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201188,"accession_number":"0000885725-24-000081","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Boston Scientific approves 2025 bonus plan and two performance share programs","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2025 Annual Bonus Plan: target bonus pool with payout 0%-150% based on global sales, adjusted EPS, operating income and ESG goals.","2025 rTSR PSP: awards 0%-200% of target based on TSR vs S&P 500 Healthcare Index over 2025-2027.","2025 Organic Net Sales PSP: awards 0%-200% of target based on organic net sales growth vs financial plan over 2025-2027.","Awards subject to Dodd-Frank clawback policy and discretionary recoupment for executive misconduct or harm.","Retirement eligibility requires age 55, 5 years service, sum ≥65; retirement before Jan 1, 2026 forfeits performance shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201187,"accession_number":"0000885725-24-000078","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Boston Scientific completes $3.7B acquisition of Axonics; enters sacral neuromodulation market","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price $71/share, equity value $3.7B, enterprise value $3.3B net of cash.","Deal expected to be immaterial to adjusted EPS in 2024-2025, accretive thereafter.","Adds Axonics' sacral neuromodulation portfolio for urinary/bowel dysfunction to Urology unit.","GAAP basis less accretive due to amortization and acquisition-related charges."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201186,"accession_number":"0000885725-24-000075","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Boston Scientific resumes AVANT GUARD trial in drug-naïve persistent AFib patients","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["AVANT GUARD trial resumed after assessment of observations and DMC input.","Study targets new population of drug-naïve patients with persistent atrial fibrillation.","No financial impact or patient enrollment numbers disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201185,"accession_number":"0000885725-24-000070","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Boston Scientific Q3 net sales $4.209B (+19.4% reported), adj. EPS $0.63 vs $0.50 YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $4.209B, up 19.4% reported, 18.2% organic; beat guidance of 13-15%.","GAAP EPS $0.32 (down from $0.34), adjusted EPS $0.63 (vs guidance $0.57-0.59).","Cardiovascular segment grew 25.0% reported; MedSurg grew 10.3%.","Full-year 2024 organic sales guidance ~15%; Q4 organic guidance 14-16%.","Completed acquisition of Silk Road Medical for stroke prevention."],"consensus_eps_estimate":null,"consensus_eps_actual":0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":12186000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217205,"accession_number":"0000885725-24-000063","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Boston Scientific appoints David Habiger to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 10 to 11 members; Habiger effective July 30, 2024.","Will serve on Audit Committee and Executive Compensation and Human Resources Committee.","Receives pro-rated cash retainer of ~$94,175 and equity award valued at ~$161,981.","Habiger is president and CEO of J.D. Power; previously led multiple tech firms.","Appointment until 2025 annual meeting; indemnification agreement to be entered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217204,"accession_number":"0000885725-24-000060","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Boston Scientific Q2 net sales $4.12B (+14.5% reported), adj EPS $0.62, above guidance; acquires Silk Road Medical","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $4.120B, up 14.5% reported (16.1% operational, 14.7% organic); GAAP EPS $0.22, adjusted EPS $0.62 vs guidance $0.57-$0.59.","Cardiovascular segment sales grew 17.8% reported; MedSurg grew 9.0%; U.S. sales up 16.9%.","Received China NMPA approval for FARAPULSE PFA System; launched AGENT Drug-Coated Balloon in U.S. and received China NMPA approval.","Announced agreement to acquire Silk Road Medical (SILK) for stroke prevention; subject to customary closing conditions.","FY2024 guidance: reported sales growth 13.5-14.5%, adj EPS $2.38-$2.42; Q3 guidance: adj EPS $0.57-$0.59."],"consensus_eps_estimate":null,"consensus_eps_actual":0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":7977000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236983,"accession_number":"0000885725-24-000050","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["5.02","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Boston Scientific appoints Dr. Cheryl Pegus to board; amends $2.75B credit facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Cheryl Pegus elected to board as tenth director, effective May 8, 2024; will serve on compensation and risk committees.","Pegus brings 25+ years of clinical and business leadership; most recently partner at Morgan Health, formerly EVP at Walmart and CMO at Walgreens.","Company amended its $2.75B revolving credit agreement, extending maturity to May 2029 for consenting lenders and adjusting the pricing grid.","Reset EBITDA exclusion cap for restructuring charges to $500M since March 31, 2024 (previously December 31, 2022)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236982,"accession_number":"0000885725-24-000048","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Boston Scientific shareholders approve bylaw amendments and elect directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected with votes ranging from 1.17B to 1.25B in favor.","Amendment to bylaws approved (1.24B for, 6.55M against); updates advance notice period to 90-120 days and universal proxy rule compliance.","Say-on-pay non-binding advisory vote approved: 1.16B for, 90.95M against.","Ratification of Ernst & Young as auditor for 2024: 1.22B for, 105.62M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236981,"accession_number":"0000885725-24-000040","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Boston Scientific Q1 beats: $3.856B sales +13.8%, adj EPS $0.56 vs $0.50-0.52 guide; raises FY outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $495M ($0.33 EPS) vs guide $0.29-0.31; adjusted EPS $0.56 vs $0.47 YoY and $0.50-0.52 guide.","Net sales $3.856B, +13.8% reported (guide 7.5-9.5%), +15.0% operational, +13.1% organic (guide 7-9%).","Cardiovascular +15.9% reported, MedSurg +10.3%; U.S. +12.7%, APAC +18.3%, Emerging Markets +22.6%.","Launched FARAPULSE PFA in U.S.; FDA approved AGENT Drug-Coated Balloon; €2.0B notes for Axonics acquisition.","FY2024 guidance: sales growth 11-13% reported, 10-12% organic; adj EPS $2.29-2.34; Q2 adj EPS $0.57-0.59."],"consensus_eps_estimate":null,"consensus_eps_actual":0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":3856000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236980,"accession_number":"0000885725-24-000037","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Boston Scientific gets FTC Second Request for Axonics merger; closing expected H2 2024","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["FTC issued Second Request under HSR Act on April 3, 2024, extending waiting period.","Waiting period now expires 30 days after substantial compliance with Second Request.","Merger expected to close in second half of 2024, subject to HSR clearance and other conditions.","Parties will promptly respond and cooperate with FTC review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":73128521082.28079,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}